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Background. Despite current medical ad-
vances, to this day there is no single medi-
cal intervention to effectively prevent or 
treat bronchopulmonary dysplasia (BPD) 
in both preterm and term infants. Along 
with protective ventilation strategies, vari-
ous drugs are being used or are being re-
searched at this very moment, with the sole 
purpose of improving the general outcome 
for these patients. Inhaled dry salt micro 
particles therapy is now one of them.
Materials and methods. This report pre-
sents five patients, diagnosed with severe 
BPD. All of them received, complemen-
tary to classical BPD management and 
respiratory support, continuous inhaled 
dry salt micro particles, via SaltMed car-
tridges, for a period of 12 to 30 days. After 
only 24 hours of administration, we were 
able to observe a significant improvement 
in respiratory function and dynamics. It 
was possible to use a lower fraction of in-
spired oxygen (FiO2), mean airway pres-
sure (MAP) and peak inspiratory pressure 
(PIP) in all mechanically ventilated pa-
tients. Higher tidal volumes were recorded 
and we observed improvement in oxygen-
ation indexes.
Conclusion. Continuously inhaled dry salt 
micro particles, administered complemen-
tary to classic BPD management, could 
improve respiratory and overall morbid-
ity and mortality in infants with any form 
of BPD. Further study of these possible 
effects is needed, as there is no data pub-
lished on this matter so far.
Key words: bronchopulmonary dysplasia 
(BPD), inhaled dry salt micro particles, oxy-
genation index (OI), fraction of inspired ox-
ygen (FiO2), mean airway pressure (MAP).
INTRODUCTION
 
Bronchopulmonary dysplasia (BPD) re-
mains one of the leading causes for chron-
ic pulmonary disease, in mostly preterm, 
but also term neonates, that requires pro-
longed administration of supplemental 
oxygen and mechanical ventilation. 
Constant improvement in neonatal man-
agement of these patients, that includes 
availability of surfactant, the possibility 
of antenatal glucocorticoid therapy and 
less invasive mechanical ventilation tech-
niques, has lowered the incidence of the 
disease and altered its characteristics. 
Thus a “new” form of BPD (1,2) is defined, 
one in which decreased septation and al-
veolar hypoplasia are the hallmarks, that 
lead to a smaller gas exchange surface. 
When accompanied by disruption in vas-
culogenesis, BPD is often complicated by 
pulmonary vascular disease, leading to 
pulmonary hypertension. (2)
A study published by the United States 
National Institute of Child Health and Hu-
man Development (NICHHD), (3) estab-
lished that the incidence of BPD rises with 
a decrease in gestational age, with 85 % of 
the 22 gestational week infants being af-
fected, in comparison to 23 % among those 
born at 28 weeks of gestational age. There 
is also a correlation with birth weight: 97% 
of cases being diagnosed among infants 
born with less than 1250 grams. (4)
Commonly cited risk factors for BPD in-
clude prematurity, mechanical ventilation 
and oxygen toxicity, antenatal and post-
natal infection, genetic predisposition and 
possible late surfactant deficiency. (1)
Prevention of BPD is very important as 
it may lead to the lowering of respiratory 
morbidity and mortality in these infants. 
Antenatal glucocorticoid therapy, fluid 
restriction, protective mechanical ventila-
tion strategies, administration of caffeine 
and possibly supplementation of vitamin 
A and late surfactant replacement are gen-
erally used. (5,6)
Management of bronchopulmonary dys-
plasia is complex and includes respiratory 
support (mechanical ventilation that uses 
smaller tidal volumes to avoid further lung 
tissue trauma and smaller fractions of in-
spired oxygen in order to lower oxygen 
toxicity, but enough to ensure adequate tis-
sue oxygenation), nutrition (increased ca-
loric intake alongside often restricted fluid 
intake) and drug therapy, with a number 
of single use or combination drugs being 
used or suggested. 
Commonly used drugs are inhaled bron-
chodilators, used to decrease airway resist-
ance in patients with acute exacerbation 
of airway obstruction, pulmonary vasodi-
lators (nitric oxide) to reduce pulmonary 
vascular resistance and inflammation in 
infants with severe BPD. (7) Systemic and 
inhaled costicosteroids (8) are being used 
for their ability to reduce inflammation 
and promote surfactant production. Diu-
retics are also commonly used in the man-
agement of BPD. Loop diuretics, like Furo-
semide (intravenous, oral and nebulized), 
reduce interstitial lung fluid, pulmonary 
vascular resistance and oxygen require-
ments. (7,9) They improve short-term lung 
mechanics, but do not decrease the need 
for ventilatory support or improve sur-
vival. (10)
Unfortunately, despite numerous medi-
cal advances, to this day there is no single 
medical intervention to prevent or treat 
BPD. A continuous search for new ways 
of targeted treatment has been launched, 
including the study of inhaled compounds 
like heparin, (11) magnesium fluoride and 
sodium fluoride (MgF, NaF), (12,13) etc., 
with regards to the possibility of them 
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reducing bronchospasm and infl amma-
tion in children with chronic pulmonary 
disease. We found that administration of 
hypertonic saline solution (3%) could de-
crease the hyperreactivity of bronchioles, 
which is sometimes associated with BPD.
In this paper we would like to present data 
obtained aft er administering inhaled dry 
salt micro particles, via SaltMed cartridges 
(produced by Tehno Bionic, Romania), to 
fi ve patients diagnosed with severe BPD, 
as a complementary intervention in their 
medical management. To this day there is 
no published data regarding this kind of 
therapy in the management of BPD.
Th e forced passage of air through a special-
ly designed dry salt SaltMed cartridge (fi g-
ure 1) containing salt microcrystals, pro-
duces erosion to a state of micro particles 
of dry sodium chloride. Th eir size ranges 
from 1 to 5 micrometers. Th is dimension 
is optimal for the dry salt micro particles 
to reach and adhere to the respiratory epi-
thelium, where it exerts a therapeutic ef-
fect.  Th e air is also fi ltered and enriched 
with ions. Total intake of salt per 24 hours 
of continuous therapy is 3.3 mg, as calcu-
lated for an adult with an estimated minute 
volume of 10 l/min. In our fi ve neonates, 
with an average weight of 3100 grams and 
with a tidal volume that ranged between 13 
and 30 ml (minute volume between 0.4-0.9 
l/min), the approximate salt intake would 
be close to 0.132-0.297 mg per day. By 
monitoring serum values for sodium and 
chloride, throughout treatment, it is pos-
sible to state that continuous inhaled dry 
salt micro particles do not at all infl uence 
electrolyte balance.
Inhaled dry salt micro particles are already 
recommended, by the manufacturer, as 
treatment for asthma, chronic pulmonary 
obstructive disease, cystic fi brosis, acute 
and chronic bronchitis in both outpatient 
and hospital care.
Th e probable eff ect of the dry salt micro 
particles is that of lowering infl ammatory 
edema, enhancing mucus mobility, quan-
tity and clearance through the airways, 
activating alveolar macrophages and fa-
cilitating phagocytosis, bactericide and 
bacteriostatic eff ect on respiratory tract 
microfl ora. Th e manufacturer reports that 
immediate eff ects of inhaled dry salt micro 
particles are as follows: increase in quan-
tity of secretions in the upper and lower 
arespiratory tract, rhinorrhea and sputum, 
activation of airway cilia and rapid clear-
ance of secretions. 
MATERIALS AND METHODS
All fi ve patients were admitted to the Neo-
natal Intensive Care Unit (NICU) at the” 
Marie Curie” Emergency Hospital for 
Children in Bucharest, Romania. Th e data 
were collected between 2014-2016. Th e se-
lected patients were all suff ering from se-
vere BPD, mechanically ventilated for long 
periods of time, with repeated unsuccess-
ful extubation attempts.
Th e infants received between 12 and 30 
days of continuous inhaled dry salt micro 
particles, in addition to the standard treat-
ment for BPD and life support.
Th e inhaled dry salt micro particles were 
delivered directly into the infant’s trachea, 
by connecting the salt cartridge to the me-
chanical ventilator circuit either in proxim-
ity to the endotracheal tube, tracheostomy 
cannula or along the inspiratory limb of 
the ventilation circuit (Figure 3). Air was 
pumped through the SaltMed cartridge 
via an electrical pump made available, in 
the SaltMed kit, by the manufacturer (fi g-
ure 2, item 2). It is important to note that 
the electrical pump delivered an additional 
fraction of inspired oxygen (FiO2) of 21% 
(atmospheric air) to each patient, 2.5 l/
min. Ventilators were set at 5 l/min. Th us 
all calculations of patient delivered FiO2, 
while delivering dry salt micro particles, 
in this paper will be a median between the 
FiO2 delivered by the mechanical ventila-
tor, as set by the physician and an addition-
al FiO2 of 21 % delivered by the air pump. 
Connecting the Salt Med device decreased 
the FiO2 delivered to the patient, at the 
same settings of the ventilator and without 
changing the pressures measured.
Each patient had a set of cartridges as-
signed for individual use. Th e cartridges 
were changed every 12 hours for optimal 
delivery of dry salt micro particles. Th e 
same protocol was followed for each pa-
tient. When available, fl ow sensors were 
also attached to the ventilator circuit.
We measured peak inspiratory pressure 
(PIP), mean airway pressure (MAP), FiO2, 
tidal volumes (VT) and oxygenation index 
(OI) before and immediately aft er con-
necting the salt cartridge to the patients 
ventilation circuit and also every day dur-
ing treatment.  We also monitored serum 
values for sodium (Na) and chloride (Cl) 
in order to verify the impact of the dry salt 




Patient #1 was a 25-day old male neonate, 
born at 34 weeks gestation, birth weight 
2340 g, Apgar score 6/7/8. He was admit-
ted to our ward for treatment of a stage 
4 intraventricular hemorrhage (IVH) 
with secondary hydrocephalus, hypoxic-
ischemic encephalopathy and meningitis, 
heart failure, pulmonary hypertension and 
renal failure. During hospitalization he 
was diagnosed with severe BPD. During 
hospitalization he also acquired two noso-
comial infections. Th e infant was intubated 
and mechanically ventilated on admission. 
He received inotropes, diuretics, antibiot-
ics and underwent external ventricular 
drainage and insertion of an internal ven-
triculo-peritoneal shunt.  Between 28-56 
days postnatal age, he had several failed 
extubation attempts. At four months post-
natal age a tracheostomy was performed 
with simultaneous administration of con-
Figure 1. SaltMed dry salt cartridge Figure 2. 1/ Dry salt cartridge 2/ Air pump 
3/ Cartridge case
Figure 3. SaltMed cartridge connected to 
inhale part of mechanical ventilation 
circuit-marked by arrow.
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tinuous inhaled dry salt micro particles 
for a period of 30 days. Before and dur-
ing the dry salt micro particles therapy, he 
also received intravenous aminophylline, 4 
times a day. We measured and monitored 
FiO2, MAP and OI during all 30 days of 
dry salt therapy (Figure 4). Even though 
we administered a lower concentration 
of oxygen (two times FiO2 set vent + one 
time 21% divided by 3) immediately aft er 
administration of dry salt particles into the 
inspiratory limb of the ventilator circuit, 
the patient reached 100% saturation, so, we 
started to decrease FiO2 from 60% to 45% 
on the fi rst day and to 30% on the second 
day. FiO2 was kept at this level until extu-
bation. MAP did not change very much 
during this period. Oxygen Index was 
lowered signifi cantly on the fi rst two days 
and was kept around 8-10 until extubation. 
Th e patient was subsequently weaned off  
the ventilator aft er 7 months of mechani-
cal ventilation. In addition, we monitored 
serum sodium and chloride values, and 
found no signifi cant impact on electrolyte 
balance (Figure 5).
Figure 4. Patient #1.  FiO2 21-100%.
FiO2, fraction of inspired oxygen; MAP, 
mean airway pressure; OI, oxygenation 
index.
Patient 1 Day 1 Day 2 Day 3 Day 7 Day 30
Na mmol/l 135.7 144.7 136.9 133.3 134.8
Cl mmol/l 98 97 94 96 97
Figure 5. Serum Na and Cl values for 
patient 1. 
Patient #2 was a male neonate, born at 30 
weeks gestation, birth weight 860g, Ap-
gar score 3/5/7, admitted to our NICU 
at 8 hours of life. Th e mother developed 
chorioamniotitis prior to giving birth. He 
was intubated and mechanically venti-
lated in the delivery room. Aft er admis-
sion to our NICU he was diagnosed with 
mild to severe respiratory distress syn-
drome (RDS) and early onset neonatal 
sepsis (he received appropriate antibiot-
ics, mild mechanical ventilation on high 
frequency oxygenation ventilation-HFOV, 
surfactant). Aft er 28 days he was extubated 
and ventilated in non invasive modes for 2 
months. For worsening x rays and work of 
breathing (WOB) he was ventilated again 
(HFOV). At 36 weeks postmenstrual age 
he was assessed and diagnosed with severe 
BPD. Aft er 2 failed extubations, the patient 
was put back on continuous invasive res-
piratory support. Inhaled dry salt therapy 
was added as a complementary therapeutic 
measure for 30 days. On the day that dry 
salt micro particle therapy was introduced 
the patient was in a mediocre state. Even 
though the patient made a mild recovery, 
during the next several weeks he began 
to slowly deteriorate, becoming critical 
by the last day of dry salt micro particle 
therapy. He also received inhaled nitric 
oxide (iNO), milrinone and prostaglandin, 
with improvement in general status. Aft er 
5 months, the patient died due to severe 
metabolic acidosis and irreversible cardio-
pulmonary complications. 
 During dry salt particle therapy we meas-
ured and monitored FiO2, MAP, tidal vol-
umes (VT), SpO2 and OI (Figure 6).  We 
monitored serum sodium and chloride 
values, and found no signifi cant impact on 
electrolyte balance (Figure 7).
Data collected revealed instant improve-
ment in expiratory tidal volume (TVe). At 
the moment of introducing dry salt par-
ticles, TVe was 13ml/minute at time zero 
and rose to 17 ml/minute aft er only ten 
minutes of inhaled dry salt micro particles 
having the same ventilator settings. Aft er 
21 days the patient developed pulmonary 
hypertension so nitrous oxide was also 
added to the patient’s treatment regimen, 
because of ongoing pulmonary function 
deterioration due to BPD and pulmonary 
hypertension. 
 
Figure 6. Patient #2. FiO2 21-100%.  
FiO2, fraction of inspired oxygen; MAP, 
mean airway pressure; OI, oxygenation in-
dex; VT, volume tidal.
Patient 2 Day 1 Day 2 Day 3 Day 7 Day 30
Na mmol/l 136.2 134.3 133.1 143.2 143.8
Cl mmol/l 99 97 99 106 122
Figure 7. Serum Na and Cl values for 
patient 2. 
Patient #3, a 38-day, term, male infant, 
birth weight 3300 g, Apgar score 9, diag-
nosed aft er birth with esophageal atresia, 
and operated on within the fi rst days of 
life. Th e infant was referred to our hospital 
because of intense labored breathing with 
low SpO2 aft er postsurgery extubation. 
Upon admission he was intubated and me-
chanically ventilated until discharge. Aft er 
further investigations he was diagnosed 
with severe tracheal stenosis. A tracheos-
tomy was performed. Between 28 and 56 
days postnatal age he was evaluated and 
diagnosed with severe BPD. He received 
a 15 day course of treatment with inhaled 
dry salt micro particles. On the day this 
therapy was initiated the patient was in a 
mediocre state. Other than mechanical 
ventilation no other medication, that could 
have impacted pulmonary function, was 
added to the patient’s plan treatment while 
receiving inhaled dry salt micro particles. 
Aft er discharge the patient was referred to 
another clinic for surgical treatment of the 
tracheal stenosis. We measured and moni-
tored FiO2, MAP, and OI during the days 
of dry salt therapy (fi gure 8). We moni-
tored serum sodium and chloride values, 
and found no signifi cant impact on elec-
trolyte balance (Figure 9). We were able to 
drop FiO2 and maintain MAP at the same 
value until discharge.
 
Figure 8. Patient #3. FiO2 21-100%.  
FiO2, fraction of inspired oxygen; MAP, 
mean airway pressure; OI, oxygenation 
index.
Patient 3 Day 1 Day 2 Day 3 Day 7 Day 15
Na mmol/l 141 140.6 138 138.5 143.9
Cl mmol/l 107 104 104 109 109
Figure 9. Serum Na and Cl values for 
patient 3 
Patient #4 was a female neonate, born at 
27 weeks gestation, birth weight 900 g, 
Apgar score 8/9. She was intubated and 
mechanically ventilated shortly aft er birth. 
Th e neonate was admitted to out unit at 
the postnatal age of 68 days. She was di-
agnosed with IVH stage 4, secondary hy-
drocephalus, cerebral abscess and men-
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ingitis. Shortly aft er being admitted, she 
developed necrotizing enterocolitis with 
multiple bowel perforations, for which she 
underwent surgery. She was treated classi-
cally during hospitalization.  At 36 weeks 
postmenstrual age she was diagnosed with 
severe BPD. Aft er one failed attempt at 
extubation, the neonate received a 12 day 
course of inhaled dry salt micro particles. 
During this treatment no other medication 
or medical intervention was performed 
that could have impacted pulmonary func-
tion. Th e patient remained stable with no 
extraordinary events occurring. Aft er 12 
days of treatment we were able to suc-
cessfully extubate the patient. Th roughout 
these 12 days we were able to lower FiO2 to 
a minimum of 21% and to stabilize MAP. 
We measured and monitored FiO2, MAP, 
and OI during dry salt therapy (Figure 10). 
We monitored serum sodium and chloride 
values, and found no signifi cant impact on 
electrolyte balance (Figure 11).
 
Figure 10. Patient #4. FiO2 21-100%.  
FiO2, fraction of inspired oxygen; MAP, 
mean airway pressure; OI, oxygenation 
index.
Patient 4 Day 1 Day 2 Day 3 Day 7 Day 12
Na mmol/l 139.6 145.7 135.9 140.1 140.2
Cl mmol/l 104 100 100 103 105
Figure 11. Serum Na and Cl values for 
patient 4.
Patient #5, a male neonate that was trans-
ferred to our clinic shortly aft er birth. 
He was born at 35 weeks gestation, birth 
weight 1530 g, Apgar score 7/8. Th e prema-
ture neonate was diagnosed with esopha-
geal atresia and Down syndrome. Surgical 
treatment consisted of primary thoraco-
scopic anastomosis of the esophageal tips. 
Complications aft er surgery occurred, 
esophageal fi stula and candida infection 
being the principal ones. Th e patient was 
ventilated for a long time, with pulmonary 
parenchymal and interstitial involvement. 
Postoperative extubation failed and me-
chanical ventilation was reinstated. As we 
presented above, during hospitalization 
he developed a systemic fungal infection 
and mediastinitis.  A bronchoscopy, aft er 
two more failed attempts to wean, was per-
formed. He was diagnosed with a moder-
ate to severe form of stenosis of the right 
main bronchus. A tracheostomy was per-
formed. Between 28 and 56 days postna-
tal age he was diagnosed with severe BPD. 
We started administering inhaled dry salt 
micro particles and continued for 30 days. 
Th e patient was stable and remained so 
until the last day of dry salt therapy. Im-
mediate improvement of tidal volume oc-
curred. Initial value was measured at 30 
ml/minute at time zero and increased to 40 
ml/minute aft er 10 minutes of inhaled dry 
salt micro particles.  We monitored FiO2, 
MAP, tidal volume and OI during dry salt 
therapy (Figure 12). We monitored serum 
sodium and chloride values, and found no 
signifi cant impact on electrolyte balance 
(Figure 13).
 
Figure 12. Patient #5. FiO2 21-100%.
  
FiO2, fraction of inspired oxygen; MAP, 
mean airway pressure; OI, oxygenation in-
dex; VT, volume tidal.
Patient 5 Day 1 Day 2 Day 3 Day 7 Day 30
Na mmol/l 134.9 137.6 135 135.1 134.2
Cl mmol/l 107 107 106 102 104
Figure 13. Serum Na and Cl values for 
patient 5. 
RESULTS
We administered continuous inhaled dry 
salt micro particles to fi ve patients diag-
nosed with severe BPD over a period of 
12-30 days. Aft er only 24 hours of ther-
apy, in some cases sooner, we were able 
to lower FiO2, MAP and PIP to ventilate 
the patients, and recorded higher tidal 
volumes. All patients had been mechani-
cally ventilated in conventional modes. 
Improved SpO2 was also seen. Th roughout 
the inhaled dry salt micro particle therapy 
period our patients had better oxygena-
tion indices. We were able to successfully 
extubate one of the patients aft er 12 days 
of continuous inhaled dry salt micro parti-
cles. In three out of fi ve cases we succeeded 
in ventilating patients with atmospheric 
air and minimum pressures. Th ey re-
mained dependent on mechanical ventila-
tion due to tracheal and bronchial illness 
(severe tracheomalacia, severe tracheal 
stenosis and moderate to severe right main 
bronchial stenosis). One of the patients 
deceased due to severe complications of 
underlying chronic pulmonary disease. 
Even in this case, we observed a brief but 
signifi cant improvement in pulmonary 
function, which was not possible to obtain 
with other measures.
A larger quantity of secretions from the 
lower and upper respiratory tract were 
noted in all patients, as was to be expected 
considering the known mechanism of ac-
tion of the dry salt micro particles on the 
respiratory epithelium. Th e increase in air-
way secretions was at its peak during the 
second and third days of therapy, started 
to decline by the seventh day and was re-
solved with fairly frequent aspirations. Af-
ter daily monitoring of serum sodium and 
chloride levels, we concluded that continu-
ous inhaled dry salt micro particles did not 
aff ect serum electrolyte balance, in any of 
our patients. 
Two out of the fi ve patients included in 
this report, received, simultaneously with 
the dry salt micro particles, medication 
that could have had infl uenced pulmonary 
function. Patient 1 was already undergoing 
treatment with Aminophylline, when dry 
salt micro particle therapy was introduced. 
No augmentation of dosage or administra-
tion schedule occurred. In the case of the 
second patient, because of progressive de-
teriorating pulmonary function and onset 
of pulmonary hypertension, it was decided 
to introduce nitric oxide, with a starting 
dose of 20 ppm. Dry salt particles brought 
about an advantage in the treatment of 
pulmonary function in this patient dur-
ing both periods of treatment, before iNO 
and simultaneously with iNO. We cannot 
speculate a connection between worsening 
pulmonary hypertension and administra-
tion of the dry salt particles. Th e other 
three patients received no other medica-
tion or therapeutic intervention that could 
have improved pulmonary outcome.
DISCUSSION
BPD continues to be one of the leading 
causes of medium and long term morbidity 
and mortality in both premature and term 
neonates. For those who are discharged 
home, an oft en lengthy period of recurrent 
acute respiratory infections lies ahead, due 
to bronchial hyperreactivity and ongoing, 
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lengthy pulmonary healing. These patients 
require prolonged hospitalization, re-
source-intensive care and costly treatment 
plans. The prospect of having a safe, easy 
to administer and cost effective means of 
reducing all of these complications related 
to BPD is of high interest. Inhaled dry salt 
micro particles appear to have an imme-
diate effect on lung parameters, although 
there is no published data to support these 
findings. The exact mechanism of action 
for these immediate augmentations in res-
piratory parameters is not yet fully known. 
CONCLUSION 
Preliminary results strongly suggest that 
inhaled dry salt micro particles could be 
a safe, easy to administer and effective 
complementary medical intervention in 
the management of neonatal chronic lung 
disease, with a possible favorable effect on 
the respiratory and overall morbidity and 
mortality of infants with BPD. It is our 
wish to continue the study of this therapy 
and its effects on patients with BPD, in a 
more randomized and controlled manner.
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